company background image
ELDN logo

Eledon Pharmaceuticals NasdaqCM:ELDN Stock Report

Last Price

US$4.66

Market Cap

US$288.5m

7D

-0.3%

1Y

232.9%

Updated

11 Dec, 2024

Data

Company Financials +

Eledon Pharmaceuticals, Inc.

NasdaqCM:ELDN Stock Report

Market Cap: US$288.5m

Eledon Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Eledon Pharmaceuticals
Historical stock prices
Current Share PriceUS$4.66
52 Week HighUS$5.54
52 Week LowUS$1.34
Beta0.76
11 Month Change-6.05%
3 Month Change84.92%
1 Year Change232.86%
33 Year Change8.12%
5 Year Change-48.46%
Change since IPO-95.94%

Recent News & Updates

Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart

Oct 29

Recent updates

Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart

Oct 29

We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Mar 22
We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

Dec 05
Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

Aug 10
Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Apr 27
We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation

Jan 05
Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation

Eledon adds 10% as FDA clears clinical trial for kidney disease candidate

Sep 06

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Invest In Growth?

Aug 31
Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Invest In Growth?

Eledon gets FDA nod to start trial of organ rejection preventing therapy

Aug 01

Eledon begins dosing in early-stage study of tegoprubart in kidney transplant patients

Jul 18

Eledon gives update on development strategy for AT-1501 in renal transplantation

Apr 26

Eledon Pharmaceuticals (NASDAQ:ELDN) Is In A Good Position To Deliver On Growth Plans

Apr 14
Eledon Pharmaceuticals (NASDAQ:ELDN) Is In A Good Position To Deliver On Growth Plans

What Type Of Shareholders Make Up Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) Share Registry?

Feb 21
What Type Of Shareholders Make Up Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) Share Registry?

Here's Why We're Not Too Worried About Novus Therapeutics' (NASDAQ:NVUS) Cash Burn Situation

Dec 30
Here's Why We're Not Too Worried About Novus Therapeutics' (NASDAQ:NVUS) Cash Burn Situation

Novus Therapeutics (NVUS) Investor Presentation - Slideshow

Dec 18

Novus Therapeutics EPS misses by $3.76

Nov 16

Enrollment underway in Novus Therapeutics' mid-stage AT-1501 trial in neuromuscular disease

Nov 02

Shareholder Returns

ELDNUS BiotechsUS Market
7D-0.3%-0.01%-0.4%
1Y232.9%10.5%30.1%

Return vs Industry: ELDN exceeded the US Biotechs industry which returned 10.5% over the past year.

Return vs Market: ELDN exceeded the US Market which returned 30.1% over the past year.

Price Volatility

Is ELDN's price volatile compared to industry and market?
ELDN volatility
ELDN Average Weekly Movement11.4%
Biotechs Industry Average Movement10.2%
Market Average Movement6.3%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.1%

Stable Share Price: ELDN's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: ELDN's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a20DA Groseledon.com

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential.

Eledon Pharmaceuticals, Inc. Fundamentals Summary

How do Eledon Pharmaceuticals's earnings and revenue compare to its market cap?
ELDN fundamental statistics
Market capUS$288.54m
Earnings (TTM)-US$24.55m
Revenue (TTM)n/a

0.0x

P/S Ratio

-11.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ELDN income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$24.55m
Earnings-US$24.55m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.41
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did ELDN perform over the long term?

See historical performance and comparison